Company · Healthtech & Bio

3PBIOVIAN

3pbiovian.com ↗ ·Pamplona ·Other

3PBIOVIAN is a pan-European biologics Contract Development and Manufacturing Organization (CDMO) formed in 2024 from the merger of 3P Biopharmaceuticals (Spain) and Biovian (Finland) under common shareholder Keensight Capital. It offers end-to-end development and GMP manufacturing for recombinant proteins, viral vectors (AAV, adenovirus), plasmid DNA and cell therapies, from preclinical through commercial supply, operating over 500 staff across facilities in Pamplona-Noáin, Spain and Turku, Finland plus a commercial office in Boston, USA.

Founded

2006

Founders

News

Rounds

Investors

SectorsBiologics manufacturing, CDMO, Cell and gene therapy, Viral vectors, Biotech Start-up MapHealthtech & Bio › Biologics manufacturing & CDMO

Profile updated 19 Jul 2026

Founders

No names on record yet.

Global models 5

National Resilience

United States · resilience.com ↗

VC-backed biopharmaceutical CDMO offering end-to-end drug substance and drug product manufacturing across multiple modalities, directly comparable to 3PBIOVIAN's biologics contract manufacturing model.

$2.0BComparable

Cellares

United States · www.cellares.com ↗

Cell therapy CDMO providing automated end-to-end manufacturing for biotech and pharma clients, matching 3PBIOVIAN's cell therapy manufacturing service line.

$612MComparable

Andelyn Biosciences

United States · www.andelynbio.com ↗

Gene therapy CDMO offering viral vector (AAV) process development and GMP manufacturing, mirroring 3PBIOVIAN's viral vector CDMO services.

$200MComparable

Forge Biologics

United States · forgebiologics.com ↗

Gene therapy CDMO providing AAV viral vector process development and commercial manufacturing, a close model match to 3PBIOVIAN's viral vector business.

$120MComparable

Exothera (Univercells)

Belgium · exothera.world ↗

European viral vector and nucleic acid CDMO spun out of Univercells, offering the same process development-to-commercial manufacturing model as 3PBIOVIAN in a similar European market.

$54MComparable

Investors 3

ERES IV (advised by Elyan Partners)

elyan.com ↗

Investor France

Keensight Capital

keensight.com ↗

Investor France

Sodena (Sociedad de Desarrollo de Navarra)

sodena.com

Investor Spain

Funding rounds

No announced rounds on record.

News & media 7

Published	Article
2025-02-13	3PBIOVIAN Marks First Year with Global CDMO Growth and Expansion ↗ PharmaSource
2024-12-02	3PBIOVIAN - Stronger Together ↗ Business Focus Magazine
2024-09-25	3PBIOVIAN receives Talent Acceleration Award at the 2024 BWB Awards ↗ 3PBIOVIAN (press release)
2024-02-01	Biovian and 3P Biopharmaceuticals Join Forces to Create 3PBIOVIAN ↗ GEN - Genetic Engineering & Biotechnology News
2023-12-21	3P Biopharmaceuticals recibe el premio a la Mejor Trayectoria Viveros CEIN en el Congreso Internacional de Emprendimiento de Alto Impacto ↗ Farmaindustrial
2023-12-21	3P Biopharmaceuticals invertirá 52 millones y creará 150 empleos en Noáin ↗ Noticias de Navarra
2021-09-29	3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA ↗ 3PBIOVIAN (press release)